GET DAILY SIGNALSVeracyte (VCYT) Shares Drop -45.5% After Q3 Earnings and Decipher Guidance Cut
Key Takeaways
- Veracyte (VCYT) shares fell roughly 45.5% over the last 30 days, driven by a sharp selloff after the company's third-quarter 2026 earnings report.
- The stock plunged about 54% in a single session after management reset growth expectations for its flagship Decipher Prostate test and trimmed forward guidance.
- Veracyte beat third-quarter revenue and earnings estimates, but weaker-than-expected Decipher prostate testing volume overshadowed the headline results.
- Several analysts cut price targets, and a number of law firms announced shareholder investigations into the company's prior statements about Decipher's growth outlook.
- The company also announced a $100 million share repurchase program and continues to expand its product portfolio, including recent launches in breast and bladder cancer testing.
- For additional context on valuation and fundamentals, explore Price Targets, Earnings, and Forecast pages.
Company Overview and Market Position
Veracyte, Inc. is a global genomics diagnostics company focused on transforming cancer care. The company develops and commercializes molecular tests that assess the unique biology of a patient's tumor to help clinicians make more informed treatment decisions. Its Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and an evidence-generation engine that supports continued innovation.
The company's portfolio includes the Afirma Genomic Sequencing Classifier for thyroid nodule assessment, the Decipher Prostate and Decipher Bladder Genomic Classifier tests, the Prosigna Breast Cancer assay, and the TrueMRD monitoring test for muscle-invasive bladder cancer. Decipher Prostate is Veracyte's largest revenue driver and a key focus for investors, while Afirma has been a consistent source of growth. Veracyte is followed closely for its ability to expand adoption, secure reimbursement, and sustain volume growth across its testing franchises. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, VCYT shares declined approximately 45.5%, from a closing price of $43.51 on October 14 to roughly $23.71 in recent trading. The bulk of that decline occurred in a single session: on November 5, the stock fell roughly 54% from its prior close of $52.52 to $24.00 after the company reported third-quarter results and issued revised forward guidance.
The quarterly picture is similar. Veracyte traded in the low-$40s in mid-August, dipped toward the high-$30s in mid-September, and then rallied to a high of $52.52 by early November before the earnings-driven collapse. Measured over the last three months, the stock is down more than 40%, with most of that loss concentrated in the days following the third-quarter report.
What Drove the Recent Selloff
The dominant catalyst was Veracyte's third-quarter 2026 earnings report, released on November 4. The company posted revenue of $151.8 million, up 15% year over year and above consensus estimates near $147 million, while adjusted earnings of $0.51 per share beat the roughly $0.41 expected. Adjusted EBITDA reached $41.2 million, or about 27% of revenue.
Despite the headline beat, investors focused on Decipher Prostate, the company's largest franchise. Decipher volume came in at roughly 29,900 tests, up 12% year over year but about 1,000 below internal expectations — marking a second consecutive quarterly shortfall. Management reduced its outlook for incremental annual Decipher volume to a range of 12,000 to 15,000 tests, down from a prior expectation of roughly 20,000, citing normalizing growth following favorable guideline updates and increasing competitive activity.
The company also narrowed its full-year 2026 revenue guidance to $590 million to $593 million from $590 million to $596 million, and introduced a preliminary 2027 outlook calling for roughly 10% total volume growth and mid-single-digit revenue growth. Analysts responded with price-target reductions, including cuts from Needham, Piper Sandler, Stephens, and Freedom Capital, while Leerink Partners downgraded the stock. Several law firms also announced investigations into whether prior statements about Decipher's growth outlook were accurate.
Quarterly Context and Broader Portfolio Momentum
Over the last quarter, Veracyte's story shifted from steady execution to a sharp reset of growth expectations. Through much of August, September, and October, the stock traded in a broad range as investors weighed strong Afirma performance and progress on newer tests against early signs that Decipher Prostate growth was moderating.
Alongside its earnings report, the company highlighted continued momentum across its broader portfolio, including the U.S. launches of Prosigna for breast cancer and TrueMRD for muscle-invasive bladder cancer, a September acquisition of Convergent Genomics to strengthen its bladder-cancer franchise, and Medicare reimbursement secured for Prosigna. The company also authorized a $100 million share repurchase program. However, the magnitude of the Decipher guidance reset — and its implications for the company's largest revenue stream — overwhelmed these positives and defined the stock's quarterly performance.
What Investors Should Watch Next
Looking ahead, investors will be watching whether Veracyte's Decipher Prostate volume stabilizes and whether management's reduced growth assumptions prove sufficiently conservative. The company's plan to expand its urology sales team by roughly 30% is expected to support growth later in 2027 and into 2028, but it will take time to show results.
Other factors to monitor include continued Afirma momentum, the commercial ramp of Prosigna and TrueMRD, and reimbursement developments across the portfolio. Pending clinical data from prospective studies evaluating Decipher, as well as competitive dynamics in prostate and bladder cancer diagnostics, could also influence sentiment. Macroeconomic conditions, healthcare spending trends, and any developments from the announced shareholder investigations round out the list of items that could affect the stock's trajectory. From what I see, these elements will be key to determining whether the recent reset creates a more stable base.
Exploring AI Tools for Market Analysis
In my own research process, I’ve turned to Tickeron’s AI Trading Bots to review automated strategies that have shown relevance across similar healthcare names. The platform offers hundreds of bots trading thousands of tickers, and the Trending AI Robots section surfaces only the top-performing and most relevant ones for quick comparison. It provides a practical way to look at different timeframes and performance metrics without replacing core fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
VCYT's Stochastic Oscillator stays in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +8.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where VCYT advanced for three days, in 205 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
VCYT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VCYT as a result. In 85 of 105 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for VCYT turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 40 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
VCYT moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VCYT crossed bearishly below the 50-day moving average on November 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VCYT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.399) is normal, around the industry mean (67.298). P/E Ratio (16.778) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (5.583) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. VCYT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VCYT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company that discovers, develops and commercializes molecular diagnostic solutions
Industry MedicalSpecialties
Advertisement